A single-arm, phase II basket trial that was focused on BRAF V600E-mutated glioma showed an increase in the response rate ((32% (95% CI 17–51)) and OS (13.7 months (95% CI 8.4–25.6)) in 31 patients with recurrent BRAF V600E-mutated GBM after they were treated with dabrafenib, a BRAF V600E inhibitor, combined with trametinib, a MEK inhibitor [63]. The gene discussed is BRAF; the disease is glioma.